Evidence map›Paper›PMID 37027002›Full record

ArticleJournal of medicinal chemistry2023

Acetyl-Click Screening Platform Identifies Small-Molecule Inhibitors of Histone Acetyltransferase 1 (HAT1).

Jitender D Gaddameedi, Tristan Chou, Benjamin S Geller, Amithvikram Rangarajan, Tarun A Swaminathan, Danielle Dixon, Katherine Long, Caiden J Golder, Van A Vuong, Selene Banuelos and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Stress triggers global histone synthesis in the liver.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jitender D GaddameediDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, United States.
Tristan ChouDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94309, United States.
Benjamin S GellerDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94309, United States.
Amithvikram RangarajanDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94309, United States.
Tarun A SwaminathanDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.
Danielle DixonDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.
Katherine LongDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.ORCID 0000-0003-1185-563X
Caiden J GolderDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.ORCID 0000-0002-0306-4793
Van A VuongDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.
Selene BanuelosDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94309, United States.
Robert GreenhouseDepartment of Otolaryngology, Stanford University School of Medicine, Stanford, California 94309, United States.
Michael P SnyderDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94309, United States.
Andrew M LipchikDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, United States.
Joshua J GruberDepartment of Internal Medicine, Hematology-Oncology Division, Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, Texas 75235, United States.ORCID 0000-0002-8642-6074
Southwestern Medical Center · USStanford University · USEugene Applebaum College of Pharmacy and Health Sciences · USUniversity of California, San Francisco · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Ritimukta Sarangi · 2020 to 2026
$43.3M
PRODUCTION CENTER FOR MAPPING REGULATORY REGIONS OF THE HUMAN GENOMEUM1HG009442 · NHGRI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2017 to 2021
$20.1M
PreCancer Atlas of Familial Adenomatous PolyposisU2CCA233311 · NCI · STANFORD UNIVERSITY · PI FORD, JAMES M., SNYDER, MICHAEL P. · 2018 to 2023
$11.6M
Metabolite sensing through the HAT1 acetyltransferase as an anti-cancer targetK08CA245024 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GRUBER, JOSHUA JAMES · 2020 to 2024
$820k
Understanding Host-Microbiota Interactions Using Integrated Personalized Omics ProfilingF32DK104460 · NIDDK · STANFORD UNIVERSITY · PI LIPCHIK, ANDREW MICHAEL · 2014 to 2017
$165k
NCATS NIH HHS UL1 TR003142NCI NIH HHS K08 CA245024NCI NIH HHS P30 CA054174NCI NIH HHS U2C CA233311NHGRI NIH HHS UM1 HG009442NIDDK NIH HHS F32 DK104460NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

HAT1 is a central regulator of chromatin synthesis that acetylates nascent histone H4. To ascertain whether targeting HAT1 is a viable anticancer treatment strategy, we sought to identify small-molecule inhibitors of HAT1 by developing a high-throughput HAT1 acetyl-click assay. Screening of small-molecule libraries led to the discovery of multiple riboflavin analogs that inhibited HAT1 enzymatic activity. Compounds were refined by synthesis and testing of over 70 analogs, which yielded structure-activity relationships. The isoalloxazine core was required for enzymatic inhibition, whereas modifications of the ribityl side chain improved enzymatic potency and cellular growth suppression. One compound (JG-2016 [

Indexed as

HistonesNeoplasmsAcetylationCell LineChromatinHistone AcetyltransferasesHumansChromatinHistone AcetyltransferasesHistones

Identifiers

PMID37027002
PMCPMC10243098
OpenAlexW4362693103

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.